Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD). The post atai Life Sciences Completes...
A Michigan lawmaker has relaunched efforts to legalize psychedelic fungi and plants with the caveat that all psychedelic-related activity does not involve...
The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide. The post...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a...
Renowned hedge fund manager and Wall Street mogul Steve Cohen is showing his confidence in the psychedelic sector. Cohen’s hedge The post Cybin Rallies...
A new study published in the “ACS Pharmacology & Translational Science” journal has revealed that psychedelics such as psilocybin may combat stress...